Disclaimer

Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up to date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breastfeeding.

Show Summary Details
Page of

Adjuvant therapy 

Adjuvant therapy
Chapter:
Adjuvant therapy
Author(s):

James Harvey

, Sue Down

, Rachel Bright-Thomas

, John Winstanley

, and Hugh Bishop

DOI:
10.1093/med/9780199215065.003.0013
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2022. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 26 May 2022

Adjuvant therapy. Advancements in adjuvant therapy for breast cancer have contributed significantly to the reduction in breast cancer mortality. Various adjuvant therapies are available to the oncologist, both in the neo-adjuvant (pre-surgery) and adjuvant (post-surgery) setting. These treatments complement surgery in reducing local disease recurrence, but also treat systemic disease effectively. The indications for radiotherapy are discussed, including the most recent trials which are currently in progress. Methods of action of the available hormonal therapies are described, along with their specific indications, and the evidence for their use. Chemotherapy is covered in some detail in this chapter, and the decision-making pathway for individual cases is explained. Finally, the benefits of new biological modifiers such as Herceptin and Lapatinib are discussed.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.